Strides gets USFDA clean closure report for New York facility

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹876.00

prior close

₹869.40

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.0%-0.0% vs market

Pharmaceuticals peers, median of 157sector-0.5%-0.5% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.9

10m

+1.3

15m

+0.4

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-1.0-0.0-0.5-0.5

Next day

-1.3-1.8+0.5-1.2-0.1

+0.6+0.8-0.2+0.5+0.0

+0.2+1.8-1.5+1.0-0.8

+0.0+1.2-1.2+0.9-0.9

-1.0+0.7-1.8+0.1-1.1

-1.9-1.5-0.5-1.4-0.6

15d

-1.8-2.5+0.6-2.9+1.1

-3.2-7.2+4.0-5.1+1.9

+11.6-8.9+20.5-7.4+19.0

+20.5+5.5+15.1+0.2+20.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Strides Pharma Inc, US step-down subsidiary, received USFDA closure report (EIR) for its Chestnut Ridge, New York formulations facility. The inspection (Dec 17 to 23, 2025) was classified as VAI (Voluntary Action Indicated), the best outcome. It included a pre-approval check for Drug-Device Combinations covering nasal sprays. The plant makes liquids, gels, hormones, modified release drugs and controlled substances for the US market.

Likely market impact

Positive. Clean EIR and VAI outcome remove regulatory overhang and support near-term US growth, especially nasal sprays pipeline.